possibl
interfer
differ
step
dolichol
pathway
protein
glycosyl
process
asparaginelink
oligosaccharid
thu
clue
role
proteinbound
carbohydr
obtain
compar
biochem
fate
function
glycosyl
protein
nonglycosyl
counterpart
protein
exhibit
differ
type
oligosaccharid
side
chain
cell
infect
envelop
virus
good
system
studi
aspect
protein
glycosyl
sinc
contain
limit
number
differ
glycoprotein
often
welldefin
function
tunicamycin
antibiot
well
sever
sugar
analogu
found
act
inhibitor
protein
glycosyl
virtu
antivir
properti
interfer
variou
step
dolichol
pathway
result
lack
function
lipidlink
oligosaccharid
precursor
compound
interfer
oligosaccharid
trim
repres
second
gener
inhibitor
glycosyl
glycosidas
inhibitor
interfer
process
glucosidas
mannosidas
resul
convers
highmannos
complextyp
oligosaccharid
block
depend
upon
compound
use
glycoprotein
contain
glucosylatedhighmannos
highmannos
hybrid
oligosaccharid
structur
instead
complex
one
biglog
consequ
alter
caus
inhibitor
manifold
increas
suscept
proteas
improp
protein
process
misfold
polypeptid
chain
loss
biolog
activ
alter
site
virusbud
name
protein
glycosyl
oligosaccharid
trim
inhibit
viral
glycoprotein
perturb
biochem
pathway
brought
two
way
genet
approach
select
mutant
lack
one
enzym
pathway
use
inhibitor
block
specif
step
pathway
use
approach
order
sequenc
intermedi
reaction
defin
particular
pathway
obtain
approach
complimentari
use
defin
pathway
invi
biosynthesi
asparaginelink
oligosaccharid
side
chain
glycoprotein
discuss
glycosyl
mutant
beyond
scope
articl
recent
review
topic
present
ix
th
intern
symposium
glycoconjug
lill
franc
juli
present
address
mrc
consult
inform
discoveri
compound
interfer
protein
glycosvl
result
dramat
increas
stuo
biolog
role
proteinbound
carbohydr
mani
compound
first
discov
antivir
effect
due
inhibit
glycosyl
viru
envelop
glycoprotein
virusinfect
cell
good
system
studi
biolog
properti
glycosyl
inhibitor
use
establish
mode
action
mani
inhibitor
well
investig
biosynthesi
membran
glycoprotein
first
gener
inhibitor
repres
tunicamycin
glucosamin
fluorosugar
block
assembl
lipidlink
oligosaccharid
precursor
gicnac
second
gener
glycosyl
inhibitor
repres
analogu
glucos
mannos
indolizidin
alkaloid
interfer
trim
glycosidas
involv
convers
highmannos
structur
complex
type
well
known
glycosyl
protein
contain
oligosaccharid
nlink
asparagin
proce
two
stage
firstli
precursor
oligosaccharid
gicnac
assembl
dolichol
pyrophosph
doipp
cartier
rough
endoplasm
reticulum
second
stage
follow
transfer
nascent
polypeptid
precursor
oligosaccharid
undergo
seri
process
reaction
rough
endoplasm
reticulum
golgi
apparatu
result
format
highmannosid
complextyp
oligosaccharid
characterist
matur
asparaginelink
glycoprotein
lipidlink
oligosaccharid
gicnac
assembl
seri
reaction
constitut
dolichol
pathway
fig
first
step
pathway
transfer
gicnacip
udpgicnac
dolichol
phosphat
pdol
give
glcnacppdol
second
gicnac
residu
transfer
udpgicnac
form
gicnac
molecul
elong
transfer
mannos
residu
directli
gdpman
yield
gicnac
intermedi
four
mannos
residu
subsequ
ad
via
intermedi
manpdol
addit
glucos
residu
via
intermedi
gicpdol
complet
assembl
lipidlink
oligosaccharid
gicnac
common
precursor
highmannosid
complextyp
oligosaccharid
side
chain
nlink
glycoprotein
transfer
complet
oligosaccharid
select
asparagin
residu
contain
sequon
asnxser
thr
cotransl
event
occur
lumin
face
rough
endoplasm
reticulum
oligosaccharid
proteinbound
undergo
sequenc
trim
reaction
fig
glucos
residu
rapidli
remov
glucosidas
ii
whilst
glycoprotein
still
endoplasm
reticulum
endoplasm
reticulum
otmannosidas
may
initi
mannos
trim
point
remov
one
mannos
residu
glycoprotein
transport
ui
illl
uiui
uljpalcttua
j
ottoalutlt
remov
mannos
residu
golgi
cmannosid
result
format
man
gicnac
intermedi
incomplet
remov
mannos
point
yield
highmannos
oligosaccharid
contain
mannos
residu
mansintermedi
substrat
gicnac
transferas
add
gicnac
free
mannos
residu
link
residu
mannosidas
ii
remov
two
mannos
residu
glcnac
transferas
mannosidas
ii
locat
medial
compart
golgi
addit
gicnac
residu
residu
galactos
fucos
sialic
acid
catalys
specif
glycosyltransferas
transgolgi
complet
assembl
complextyp
oligosaccharid
work
conduct
sever
laboratori
includ
demonstr
possibl
uop
gi
p
interfer
differ
step
dolichol
pathway
oligosaccharid
process
initi
inhibitor
discov
block
protein
glycosyl
interf
step
dolichol
pathway
fig
antibiot
tunicamycin
best
wellknown
inhibitor
group
wealth
inform
concern
mode
action
biolog
effect
differ
system
inhibit
first
step
dolichol
pathway
name
format
glcnaeppdol
pdol
udpgiena
appear
structur
analogu
udpgicnac
compos
uracil
fatti
acid
gicnac
tunicamin
unusu
aminodeoxydialos
tunicamycin
gener
name
mixtur
close
relat
structur
contain
variat
fatti
acid
moieti
sever
antibiot
affect
biosynthesi
lipid
intermedi
involv
bacteri
cell
wall
format
interfer
dolichol
pathway
peptid
antibiot
amphomycin
tsushimyein
showdomycin
inhibit
format
dolichollink
monosaccharid
wherea
bacitracin
found
interfer
sever
differ
reaction
dolichol
pathway
depend
upon
system
use
elong
man
gicnac
hen
oviduct
membran
format
gicnacppdol
calf
pancrea
microsom
glcnac
synthesi
yeast
membran
report
sensit
bacitracin
diumycin
found
inhibit
manpdol
format
also
format
glcnacppdol
glcnac
addit
glcnac
gicnacppdol
sensit
inhibit
transfer
glcnacip
pdol
sugar
analogueswer
detect
inhibitor
protein
glycosyl
virtu
antivir
properti
thu
analogu
glucos
mannos
glucosamin
found
interfer
glycosyl
viral
membran
glycoprotein
inhibit
assembl
lipidlink
oligosaccharid
precursor
gicnac
recent
mannos
analogu
contain
modif
hydroxyl
group
synthes
also
found
similar
antivir
effect
effect
aforement
sugar
analogu
dolichol
pathway
vivo
list
tabl
except
glucosamin
sugar
analogu
metabolis
order
exert
inhibitori
effect
thu
respect
nucleosid
diphosph
ester
detect
cell
treat
sugar
analogu
vitro
deriv
actual
inhibitori
agent
tabl
ii
list
mode
action
deriv
gdpderiv
substrat
biosynthesi
respect
monosaccharidespdol
sinc
competit
inhibitor
gdpman
pdol
mannosyltransferas
addit
format
correspond
label
nucleotid
sugar
analogu
observ
vitro
contrast
readili
synthesis
use
chick
embryo
cell
membran
prepar
wherea
bhk
cell
label
one
metabolit
detect
synthesi
observ
vitro
membran
prime
pdol
taken
cell
tissu
cultur
howev
interest
synthesis
correspond
gdpderiv
look
effect
dolichol
pathway
vitro
strong
inhibitor
manpdol
synthesi
format
lipidlink
oligosaccha
tabl
format
manpdol
gicpdol
pool
site
udpglc
reduc
major
lipidlink
oligosaccharid
glcnac
protein
glycosyl
altern
pathway
form
ation
manpdol
mannosyl
gicnac
format
manpdol
gicpdol
mang
gicnac
major
lipidlink
oligosaccharid
possibl
incorpor
lipidlink
oligosaccharid
possibl
incorpor
lipidlink
oligosaccharid
chick
embryo
cell
lipidlink
oligosaccharid
assembl
inhibit
mana
gicnac
accumul
mdck
cell
low
glen
concentr
mm
mant
gicnac
accumul
high
concentr
glen
mm
glcnac
accumul
glen
inhibit
revers
accumul
man
gicnac
gicnac
format
manpdol
glcpdol
glcnaeppdol
due
trap
dolp
pdol
elong
gicnac
dol
due
incorpor
instead
man
effect
lipidlink
saccharid
format
vitro
format
finol
phosphat
mannos
rat
liver
microsom
inhibit
format
manp
dol
glc
pdol
gicnacppdol
due
trap
doip
format
man
gicnac
inhibit
format
manpdol
glcpdol
gicnacppdol
due
trap
dolp
w
mcdowel
rt
schwarz
unpublish
data
mannosyl
man
gicnac
effect
dolichollink
monosaccharid
format
manpdol
glcpdol
gicnacpp
dol
format
due
trap
dolp
may
replac
man
reidu
lipidlink
oligosaccharid
come
directli
gdpman
format
manpdol
glcpdol
glcnacppdol
due
trap
doip
w
mcdowel
rt
schwarz
unpublish
data
format
gicpdol
format
gicpdol
format
gicpdoi
format
gicpdol
due
trap
dolp
gicnpdol
abbrevi
sugar
analogu
see
tabl
high
electroneg
fluorin
present
seem
advers
effect
enzymesubstr
interact
shown
fact
ki
time
higher
also
much
better
inhibitor
manpdol
format
noninhibitori
concentr
least
mention
glucosamin
rather
metabolit
inhibitor
protein
glycosyl
howev
glucosamin
form
udpglucosamin
also
inhibitor
point
udpglucosamin
product
galactosamin
glucosamin
metabol
udpglucosamin
act
analogu
udpgic
vitro
inhibit
gicpdol
synthesi
result
format
glucosaminepdoi
longer
transfer
gicnac
rais
possibl
may
deplet
pdol
pool
consequ
inhibit
protein
glycosyl
cell
treat
galactosamin
indic
nucleotid
ester
sugar
analogu
interfer
assembl
lipidlink
oligosaccharid
thu
protein
glycosyl
littl
known
effect
modif
nucleosid
moieti
sugar
nucleotid
tackl
two
approach
use
first
sugar
nucleotid
contain
synthesis
second
ribos
uridin
moieti
period
oxidis
mild
condit
produc
suicid
substrat
fu
uuiiti
tllllll
lli
iluioi
iu
fuijv
uiu
iiu
fudpglcnac
found
altern
substrat
format
glcpdol
gicnac
respect
fudpgic
good
substrat
udpgic
wherea
fudpglcnac
poor
substrat
compar
udpgicnac
period
oxidis
sugar
nucleotid
oudpgic
oudpgicnac
suicid
substrat
inhibit
format
gicpdol
gicnac
respect
oudpgicnac
preferenti
inhibit
addit
gicnac
glcnacppdol
therefor
one
hand
introduct
fluoro
group
posit
uracil
ring
udpsugar
produc
altern
substrat
wherea
hand
chemic
modif
period
oxid
result
inhibitor
convers
glucosyl
highmannos
precursor
oligosaccharid
transfer
protein
oligosaccharid
complextyp
involv
concert
action
glucosidas
mannosidas
therefor
obviou
search
potenti
inhibitor
trim
pathway
among
known
inhibitor
glycosidas
result
search
quit
product
sever
use
inhibitor
found
fig
nevertheless
test
nojirimycin
acarbos
either
specif
inhibitor
effect
first
report
trim
inhibitor
indolizidin
alkaloid
swainsonin
discov
virtu
properti
induc
condit
ident
human
mannosidosi
sheep
cattl
eaten
wild
plant
swainsona
canescen
australia
locowe
usa
alkaloid
isol
plant
found
potent
inhibitor
lysosomai
jack
bean
mannosidas
subsequ
found
prevent
convers
highmannos
oligosaccharid
complextyp
variou
mammalian
cell
line
result
format
hybrid
oligosaccharid
endoglucosaminidas
hsensit
vitro
experi
golgi
mannosidas
mannosidas
ii
show
swainsonin
specif
inhibit
tll
ltt
qlll
vlll
glucosidas
inhibitor
bromoconduritol
next
trim
inhibitor
report
bromoconduritol
activ
sitedirect
coval
inhibitor
aglucosidas
obtain
chemic
synthesi
myoinositol
incub
rat
liver
glucosidas
prepar
bromoconduritol
inhibit
releas
innermost
glucos
residu
oligosaccharid
result
accumul
influenza
virtsinfect
chick
embryo
cell
treat
bromoconduritol
format
complextyp
oligosaccharid
inhibit
viral
glycoprotein
contain
highmannos
oligosaccharid
composit
glcnac
thu
vitro
vivo
data
indic
bromoconduritol
inhibitor
glucosidas
ii
even
though
oligosaccharid
glc
residu
rather
glc
residu
accumul
possibl
explan
appar
anomali
could
bromoconduritol
interfer
bind
oligosaccharid
activ
site
remov
glc
residu
glcnac
rather
catalyt
site
enzym
potent
inhibitor
glucosidas
glucosidas
ii
vitro
sensit
trim
glucosidas
drug
vari
depend
upon
enzym
sourc
thu
enzym
yeast
inhibit
enzym
activ
obtain
glucosidas
glucosidas
ii
wherea
calf
liver
microsom
inhibit
obtain
glucosidas
tlm
glucosidas
ii
intact
cell
inhibit
format
complextyp
oligosaccharid
highmannos
oligosaccharid
composit
gicnac
accumul
oligosaccharid
contain
glucos
residu
account
mixtur
indic
vivo
whilst
interfer
action
trim
glucosidas
preferenti
inhibit
glucosidas
ii
apart
trim
inhibitor
may
also
interfer
format
lipidlink
oligosaccharid
precursor
gicamang
glcnac
thought
inhibitori
effect
may
relat
mechanist
inhibit
lipidlink
oligosaccharid
biosynthesi
glu
osamin
inde
methyl
ring
nitrogen
suppress
inhibit
lipidlink
synthesi
result
mdn
potent
inhibitor
glucosidas
parent
compound
vivo
mdn
inhibit
format
complextyp
oligosaccharid
highmannos
oligosaccharid
composit
glcnac
accumul
effect
mdn
format
complextyp
oligosaccharid
compar
use
cultur
intestin
epitheli
cell
found
mm
requir
produc
maxim
inhibit
wherea
mm
nmethylderiv
requir
produc
effect
addit
presenc
nmethylderiv
oligosaccharid
contain
glucos
residu
contrast
sampl
therefor
prefer
deriv
inhibit
glucosidas
without
ad
complic
interf
lipidlink
oligosaccharid
synthesi
castanospermin
next
inhibitor
appear
like
swainsonin
plant
alkaloid
isol
seed
castanospermum
austral
toxic
caus
gastrointestin
irrit
eaten
livestock
found
potent
inhibitor
lysosom
enzym
aglucosidas
fibroblast
extract
well
almond
without
effect
yeast
aglucosidas
treatment
cell
castanospermin
inhibit
format
complextyp
oligosaccharid
glycoprotein
equip
highmannos
oligosaccharid
contain
glucos
residu
similar
nmethylldeoxynojirimycin
castanospermin
appear
nontox
treat
cell
effect
format
lipidlink
oligosaccharid
protein
synthesi
observ
thu
castanospermin
like
nmethylldeoxynojirimycin
good
inhibitor
trim
glucosidas
without
detriment
effect
cellular
filnction
success
deriv
nojirimycin
glucosidas
trim
inhibitor
led
synthesi
test
mannos
analogu
dmm
inhibitor
trim
mannosidas
shown
inhibitor
golgi
mannosidas
cell
treat
drug
convers
highmannos
oligosaccharid
complextyp
block
major
oligosaccharid
present
glycoprotein
mang
gicnac
confirm
golgi
mannosidas
sensit
enzym
dmm
competit
inhibitor
mannosidas
ki
rat
liver
enzym
rat
liver
endoplasm
reticulum
omannosidas
sensit
drug
one
disadvantag
use
dmm
trim
inhibitor
lie
fact
also
act
inhibitor
format
lipidlink
oligosaccharid
tiusti
w
mcdowel
rt
schwarz
unpublish
data
chick
embryo
cell
instanc
inhibit
lipidlink
oligosaccharid
synthesi
drastic
inhibit
mm
wherea
bhk
mdck
cell
littl
inhibit
concentr
dmm
suffici
suppress
mannosidas
activ
nmethyl
suppress
inhibit
lipidlink
oligosaccharid
result
nmethylldeoxymannojirimycin
potent
mannosidas
inhibitor
aforement
inhibitor
meantim
becom
commerci
avail
nevertheless
consider
interest
develop
novel
compound
exhibit
differ
specif
mode
action
toward
glycosidas
one
group
compound
polyhydroxyl
piperidin
pyrrolidin
potenti
glycosidas
inhibitor
due
structur
resembl
pyranos
sugar
compound
belong
group
isol
plant
found
potent
inhibitor
glycosidas
chemic
synthesi
made
avail
amount
suitabl
test
inhibitor
glycoprotein
oligosaccharid
process
dmdp
first
new
type
use
trim
inhibitor
isol
leav
derri
elliptica
seed
lonchocarpu
sericeu
synthesi
glucos
report
dmdp
potent
inhibitor
concentr
requir
give
inhibit
time
time
lower
respect
howev
conflict
report
concern
effect
dmdp
oligosaccharid
process
vivo
first
report
influenza
virusinfect
mdck
cell
dmdp
inhibit
trim
glucosidas
sinc
treat
cell
convers
highmannos
oligosaccharid
complextyp
oligosaccharid
inhibit
oligosaccharid
composit
gicnac
accumul
viral
glycoprotein
subsequ
studi
use
cultur
intestin
epitheli
cell
format
complextyp
side
chain
also
inhibit
mixtur
highmannos
oligosaccharid
found
major
oligosaccharid
composit
glcnac
thu
intestin
cell
main
effect
dmdp
seem
direct
toward
trim
mannosidas
situat
influenza
virusinfect
chick
embryo
cell
differ
yet
appropri
condit
glucosyl
highmannos
oligosaccharid
composit
gicnac
present
viral
glycoprotein
form
presenc
dmdp
predomin
structur
gicnac
clear
effect
dmdp
oligosaccharid
process
mdck
cell
intestin
epitheli
cell
chick
embryo
cell
differ
may
relat
proton
ring
nitrogen
result
chang
ph
uptak
cell
transport
penetr
endoplasm
reticulum
membran
sinc
nonproton
form
dmdp
activ
inhibitor
analog
compound
dim
design
amannosidas
inhibitor
synthesis
chemic
benzyladmannopyranosid
effect
inhibitor
jack
bean
amannosidas
swainsonin
exhibit
inhibit
lysosom
tmannosidas
also
sensit
inhibit
much
higher
concentr
need
inhibit
case
inhibit
competit
dmdp
nonproton
form
effect
inhibitor
influenza
virusinfect
mdck
cell
treat
dim
synthesi
complextyp
oligosaccharid
inhibit
maxim
major
highmannos
oligosaccharid
accumul
composit
mang
gicnac
indic
dim
inhibit
mannosidas
addit
oligosaccharid
synthes
presenc
dim
hybrid
type
suggest
dim
also
exert
effect
mannosidas
ii
thu
intact
cell
dim
act
inhibit
mannosidas
mannosidas
ii
although
less
effect
inhibitor
format
complextyp
oligosaccharid
swainsonin
anothtr
chemic
synthesis
iminopentitol
dia
subsequ
found
ident
alkaloid
extract
legum
angylocalyx
boutiqueanu
dia
potent
compeut
inhibitor
yeast
aglucosidas
inhibit
also
effect
almond
jack
bean
amannosidas
concentr
requir
inhibit
higher
yeast
tglucosidas
treatment
influenza
virusinfect
chick
embryo
cell
dia
medium
contain
mm
glucos
resuit
inhibit
convers
highmannos
oligosaccharid
complextyp
glucosyl
highmannos
oligosaccharid
accumul
howev
glucos
medium
reduc
ram
glucosyl
highmannos
oligosaccharid
composit
glc
nac
accumul
suggest
dia
inhibit
glucosidas
result
obtain
dmdp
dim
dia
demonstr
nitrogen
analogu
furanos
effect
glycosidas
inhibitor
polyhydroxyl
pyrrolidin
piperidin
rel
easi
synthesis
doubt
array
compound
inhibit
varieti
differ
glycosidas
use
investig
structurefunct
relationship
oligosaccharid
well
experiment
induc
condit
studi
model
genet
inherit
disord
metabol
aforement
inhibitor
interact
respect
sensit
enzym
competit
manner
suicid
substrat
offer
altern
mean
inhibit
coval
modif
activ
site
enzym
glycosylmethylpnitrophenyltrizen
recognis
potenti
suicid
substrat
glycosidas
inactiv
bacteri
lysosom
basi
find
aomannopyranosylmethylpnitrophenyltriazen
mmnt
synthesis
test
mannosidas
inhibitor
lysosom
jack
bean
amannosidas
inactiv
golgi
mannosidas
golgi
mannosidas
ii
endoplasm
reticulum
amannosidas
resist
inhibit
mannosidas
obtain
mm
mmnt
hepatocyt
treat
mmnt
alacid
glycoprotein
glycosyl
highmannos
oligosaccharid
composit
gicnac
influenza
viru
glycoprotein
equip
mainli
highmannos
oligosaccharid
composit
gicnac
synthesis
infect
chck
embryo
cell
treat
mmnt
thu
vivo
mmnt
appear
interfer
golgi
mannosidas
activ
inhibit
protein
glycosyl
divers
biolog
effect
depend
upon
glycoprotein
cell
type
investig
use
trim
inhibitor
possibl
investig
specif
chang
oligosaccharid
composit
affect
intraceuular
transport
polypeptid
fold
viru
matur
well
rel
import
highmannos
complextyp
oligosaccharid
although
th
effect
trim
inhibitor
studi
mani
system
virusinfect
cell
provid
interest
biolog
phenomena
list
tabl
iii
shown
tabl
iii
format
influenza
virus
rou
sarcoma
viru
affect
inhibitor
glucosidas
mannosidas
trim
one
except
fowl
plaqu
viru
strain
influenza
viru
haemagglutinin
metabol
unstabl
oligosaccharid
trim
inhibit
glucosidas
ii
inhibitor
bromoconduritol
oligosaccharid
composit
glcr
glcnac
present
glycoprotein
appar
uncleav
haemagglutinin
metabol
stabl
independ
oligosaccharid
composit
cleavag
haemagglutinin
containjng
gicna
oligosaccharid
yield
ha
subunit
resist
degrad
proteas
wherea
cleavag
haemagglutinin
contain
glcnac
yield
product
suscept
proteolyt
degrad
probabl
result
misfold
essenti
role
glucos
trim
establish
function
conform
viral
glycoprotein
come
observ
made
influenza
viru
also
format
infecti
particl
inhibit
suscept
proteolyt
degrad
effect
viru
particl
format
effect
viru
particl
format
sulphat
nwsinfect
mdck
cell
inhibit
cs
effect
viru
particl
format
viru
particl
format
inhibit
mm
mmnt
activ
haemagglutinin
neuraminidas
unaffect
mm
mmnt
viru
particl
format
inhibit
effect
temperaturesensit
transport
gprotein
cell
surfac
unaffect
effect
viru
particl
format
effect
viru
particl
format
surfac
express
gprotein
viru
particl
format
inhibit
effect
temperaturesensit
dn
cs
mdn
cleavag
block
cell
surfac
express
viru
bud
intern
membran
effect
viru
particl
format
decreas
viru
particl
format
cleavag
delay
accumul
intracellularli
effect
great
mdn
cs
effect
viru
particl
format
cleavag
precursor
affect
decreas
incorpor
env
protein
particl
decreas
viru
format
transport
proteolyt
cleavag
env
protein
affect
growth
transform
cell
becom
serum
depend
poor
growth
soft
agar
transform
properti
cell
alter
transform
state
cell
maintain
infect
particl
reduc
inhibit
syncytium
format
effect
cleavag
precursor
still
express
cell
surfac
sindbi
viru
vesicular
stomat
viru
mous
hepat
viru
tabl
iii
result
corrobor
observ
made
nonvir
system
deal
secret
surfac
express
glycoprotein
consensu
suggest
glucos
trim
may
import
initi
stage
protein
fold
polypeptid
chain
releas
ribosom
mannos
trim
hand
appear
import
although
mannosidas
inhibitor
swainsonin
inhibit
complextyp
oligosaccharid
format
better
glucosidas
inhibitor
usual
mannos
trim
take
place
even
glucos
trim
inhibit
cf
oligosaccharid
form
presenc
bromoconduritol
mdn
castanospermin
incomplet
inhibit
complextyp
oligosaccharid
format
attribut
presenc
golgi
endoodmannosidas
remov
glucosylmannos
disaccharid
yield
mana
gicnac
provid
altern
rout
oligosaccharid
process
sequenti
action
glucosidas
ii
mannosidas
initi
stage
mannos
trim
import
sindbi
virusbhk
system
determin
final
destin
viral
envelop
glycoprotein
sinc
treatment
mannosidas
inhibitor
result
bud
viru
intern
membran
effect
also
observ
cell
treat
monensin
mutant
cell
line
observ
concern
biolog
effect
trim
inhibitor
confirm
nlink
oligosaccharid
serv
structur
role
time
polypeptid
fold
agreement
idea
exist
singl
pathway
oligosaccharid
process
demand
precursor
oligosaccharid
meet
structur
requir
sensit
glycoprotein
result
treatment
cell
transform
retrovirus
trim
inhibitor
tabl
iii
add
weight
notion
everi
system
examin
right
generalis
made
concern
effect
inhibitor
oligosaccharid
process
thu
one
hand
avian
retrovirus
rou
sarcoma
viru
avian
erythroblastosi
viru
appear
unaffect
chang
oligosaccharid
composit
envelop
glycoprotein
oncogen
product
wherea
format
friend
mink
cell
focusinduc
murin
leukaemia
viru
transform
properti
felin
sarcoma
viru
vfin
oncogen
product
affect
current
topic
interest
observ
viru
respons
caus
diseas
aid
human
immunodefici
viru
hiv
appear
sensit
effect
glucosidas
trim
inhibitor
presenc
castanospermin
envelop
glycoproteinmedi
syncytium
format
hiv
infect
tcell
inhibit
thought
perturb
carbohydr
sidechain
hiv
envelop
glycoprotein
result
lower
affin
receptor
tcell
decreas
syncytium
format
attribut
inhibit
process
precursor
protein
result
decreas
cell
surfac
express
matur
envelop
glycoprotein
addit
step
involv
membran
fusion
bind
antigen
may
affect
antivir
effect
exhibit
glucosidas
trim
inhibitor
suggest
modif
glycosyl
state
hiv
envelop
glycoprotein
may
use
treatment
hiv
infect
observ
inhibitor
protein
glycosyl
oligosaccharid
trim
antivir
effect
lead
question
whether
could
use
chemotherapeut
agent
certainli
mani
trim
inhibitor
appear
nontox
potenti
use
antivir
chemotherapi
indic
find
hiv
inhibitor
lipidlink
oligosaccharid
assembl
tunicamycin
toxic
fact
glycosyl
inhibitor
alreadi
tri
antivir
agent
localis
herp
viru
infect
use
treat
herp
simplex
virusinduc
keratin
rabbit
human
genit
herp
simplex
viru
infect
howev
signific
result
question
studi
fail
show
effect
deoxyglucos
discourag
work
treatment
herp
infect
glycosyl
inhibitor
addit
potenti
antivir
properti
inhibitor
oligosaccharid
trim
may
use
immunomodul
treatment
cancer
tumour
tumour
invas
metastasi
presum
mediat
via
interact
oligosaccharid
locat
cell
surfac
would
therefor
expect
chang
oligosaccharid
composit
cell
surfac
may
alter
bind
tumour
cell
thu
spread
cancer
swainsonin
found
use
immunomodul
thu
treatment
murin
lymphoma
cell
swainsonin
inhibit
pulmonari
colonis
immunodefici
mice
growth
sarcoma
inhibit
metastasi
melanoma
lung
reduc
ideal
antivir
agent
act
viru
infect
cell
thu
minimis
toxic
problem
vein
antiherpet
drug
acyclovir
guanin
activ
virusinfect
cell
virusencod
thymidin
kinas
produc
inhibitor
dna
polymeras
analog
manner
may
possibl
develop
virusspecif
inhibitor
glycosyltransferas
although
synthesi
viral
dna
undoubtedli
prime
target
antivir
chemotherapi
nucleosid
analogu
compound
may
also
interfer
process
glyeosyl
viral
glycoprotein
format
sugar
nucleotid
analogu
interfer
glycosyltransferas
involv
glycosyl
pathway
inde
result
e
inhibit
galactosyl
nand
olink
oligosaccharid
herp
simplex
glycoprotein
indic
potenti
nucleosid
analogu
glycosyl
inhibitor
